Alzheimer’s and Dementia Guidelines and Tables

Introduction The purpose of this guide is to provide convenient and useful information on about Alzheimer's disease and dementias of late life. The information includes selected facts, diagnostic criteria tables, descriptions of selected tests and screens, guidelines, clinical pharmacological data and references. This guide is divided into several sections: Background factsDiagnostic aids and criteria for dementia diagnosesMedications used for Alzheimer's disease and dementia Basic information on marketed treatments is provided although the treatment may not be FDA approved for this use. Approved cholinesterase inhibitors, memantine, and monoclonal antibodies are listed. No treatment is recommended or endorsed, however. This guide does not address the evidence base for the efficacy of the treatments listed. <i>Caveats</i>: Except for treatments above, discussions of medications for people with dementia nearly always involve off label use. For example, antidepressants and antipsychotics are indicated in the FDA-approved prescribing information for major depression and schizophrenia, and not for depressive symptoms or the delusions or hallucinations occurring within the context of dementia with two exceptions. In these instances, the doses listed are for reference only and should not be considered as recommendations or appropriate use. Physicians should consult the product package labeling for any drug mentioned.

Authors

Institutions

Publication Details

Journal
Psychopharmacology Bulletin
Published
2025-08-12
DOI
https://doi.org/10.64719/pb.4463
Citations
2
Primary Topic
Clinical practice guidelines implementation
Type
article
Field-Weighted Citation Impact
1.88
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Alzheimer’s and Dementia Guidelines and Tables

Lon S. Schneider
2 citations
Psychopharmacology Bulletin
Clinical practice guidelines implementation
1.88
article

Alzheimer’s and Dementia Guidelines and Tables

Lon S. Schneider
article en
2 citations

Abstract

Introduction The purpose of this guide is to provide convenient and useful information on about Alzheimer's disease and dementias of late life. The information includes selected facts, diagnostic criteria tables, descriptions of selected tests and screens, guidelines, clinical pharmacological data and references. This guide is divided into several sections: Background factsDiagnostic aids and criteria for dementia diagnosesMedications used for Alzheimer's disease and dementia Basic information on marketed treatments is provided although the treatment may not be FDA approved for this use. Approved cholinesterase inhibitors, memantine, and monoclonal antibodies are listed. No treatment is recommended or endorsed, however. This guide does not address the evidence base for the efficacy of the treatments listed. <i>Caveats</i>: Except for treatments above, discussions of medications for people with dementia nearly always involve off label use. For example, antidepressants and antipsychotics are indicated in the FDA-approved prescribing information for major depression and schizophrenia, and not for depressive symptoms or the delusions or hallucinations occurring within the context of dementia with two exceptions. In these instances, the doses listed are for reference only and should not be considered as recommendations or appropriate use. Physicians should consult the product package labeling for any drug mentioned.

Psychopharmacology BulletinVol. 53(2)
University of Southern California (US)
Good health and well-being
Openalex Percentile: Top 20%
Clinical practice guidelines implementation
1.88
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Alzheimer’s and Dementia Guidelines and Tables — Lon S. Schneider · Psychopharmacology Bulletin (2025) | TGRS Research Map | TGRS